Magle Chemoswed Holding (MAGLE.ST) Stock Analysis & AI Equity Report
Magle Chemoswed Holding (MAGLE.ST) overview
Magle Chemoswed Holding (MAGLE.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Magle Chemoswed Holding reported revenue of SEK 283m and operating profit of SEK -136m; the year-end share price was 17.60 SEK and market capitalisation was SEK 363m. Magle Chemoswed Holding is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Magle Chemoswed Holding's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Magle Chemoswed Holding
Magle Chemoswed Holding AB is a Swedish contract development and manufacturing organization serving pharmaceutical and medical device customers. The company provides services from process development and analytical support through GMP manufacturing, fill-finish, freeze-drying, and related regulatory support. It also develops and supplies products and technologies based on its proprietary microsphere platform.
Generate the Magle Chemoswed Holding report
Magle Chemoswed Holding is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Magle Chemoswed Holding and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Magle Chemoswed Holding
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.